Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bearish -75

MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller ...

AI-generated analysis

πŸ“… Investors with substantial losses in Regeneron common stock between August 1, 2025, and May 15, 2026, have until September 14, 2026, to seek appointment as lead plaintiff of the class action lawsuit.

βš–οΈ The lawsuit charges Regeneron Pharmaceuticals, Inc. and certain top executives with violations of the Securities Exchange Act of 1934 regarding false and misleading statements about the Phase III Fianlimab-Libtayo Study.

πŸ“‰ Allegations state that defendants created a false impression that the study was well-poised for success while minimizing risks arising from a prolonged event rate slowdown and flawed statistical assumptions.

πŸ”¬ The complaint asserts that Regeneron failed to disclose that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies during the Class Period.

πŸ’° According to the complaint, Regeneron stock declined more than 6% on April 29, 2026, after defendants allegedly disclosed that the Phase III Fianlimab-Libtayo Study had been altered to expand patient eligibility for analysis.

πŸ“‰ The complaint alleges that Regeneron stock dropped nearly 10% on May 15, 2026, following a press release announcing that the Phase 3 Trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival.

⚠️ Robbins Geller Rudman & Dowd LLP is soliciting information from investors to potentially serve as lead plaintiff and direct the Regeneron class action lawsuit on behalf of all other class members.

Risk Factors
  • The company is alleged to have made false and/or misleading statements and/or failed to disclose that its Phase III Fianlimab-Libtayo Study was well-poised for success while minimizing risks to the study's odds of achieving its primary endpoint.
  • Allegations state that Regeneron's preliminary statistical assumptions were fundamentally flawed and that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies.
  • The lawsuit alleges that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
  • On April 29, 2026, defendants allegedly disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for analysis of progression-free survival.
  • The complaint states that on April 29, 2026, the price of Regeneron stock declined more than 6% following the alleged disclosure regarding the alteration of the Phase III Fianlimab-Libtayo Study.
  • On May 15, 2026, Regeneron allegedly announced that the Phase 3 Trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival.
  • The complaint alleges that on May 15, 2026, the price of Regeneron stock dropped nearly 10% following the announcement that the trial failed to reach statistical significance.
Full Analysis
Robbins Geller Rudman & Dowd LLP is soliciting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to serve as lead plaintiff in a shareholder class action lawsuit captioned Cheatham v. Regeneron Pharmaceuticals, Inc. The firm invites purchasers or acquirers of common stock between August 1, 2025, and May 15, 2026, to submit information by September 14, 2026, to potentially lead the litigation. The lawsuit alleges that Regeneron and its top executives violated the Securities Exchange Act of 1934 by making false or misleading statements regarding the Phase III Fianlimab-Libtayo Study. Specifically, defendants are accused of creating a false impression that the study was well-poised for success while minimizing risks related to a prolonged slowdown in event rates and fundamental flaws in preliminary statistical assumptions. According to the complaint, Regeneron allegedly failed to disclose that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies. The allegations further state that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm. These disclosures allegedly caused significant stock price declines. On April 29, 2026, during Regeneron's first quarter earnings call, defendants allegedly disclosed that the Phase III Fianlimab-Libtayo Study had been altered to expand the number of patients eligible for analysis of progression-free survival. Following this news, the complaint states that Regeneron stock declined more than 6%. Subsequently, on May 15, 2026, after-market trading saw Regeneron issue a press release announcing that the Phase 3 Trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival. The complaint alleges this news caused the price of Regeneron stock to drop nearly 10%.